Ignite Creation Date:
2024-05-06 @ 3:45 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04742777
Status:
RECRUITING
Last Update Posted:
2024-02-23
First Post:
2021-02-01
Brief Title:
Effect of mTOR Inhibition Other Metabolism Modulating Interventions on the Elderly SubStudy Rapa cMRI to Evaluate Cardiac Function
Sponsor:
The University of Texas Health Science Center at San Antonio
Organization:
The University of Texas Health Science Center at San Antonio
Study Overview
Official Title:
Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly Immune Cognitive and Functional Consequences Substudy E - RAPA cMRI With LGE
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
mTOR
Brief Summary:
The ability to mount an effective immune response declines with age leaving the elderly increasingly susceptible to infectious diseases and cancer Rapamycin an FDA approved drug to prevent transplant rejection increases the lifespan and healthspan of mice and ameliorates age-related declines in immune responsiveness cancer survival and cognition in laboratory animals Investigators are conducting a translational trial to test whether rapamycin also improves life functions in humans focusing on elderly persons aged 70-95
Substudy E will evaluate the Rapamycin and Cardiac Function
Substudy E will evaluate the Rapamycin and Cardiac Function
Detailed Description:
The main study has completed and results are reported NCT02874924
Purpose of Sub-study E - Rapamycin and cMRI to evaluate cardiac function
The over-arching hypothesis is that RAPA treatment will effect simultaneous improvement in parameters known to be negatively impacted by aging For example systemic inflammation is higher in older individuals and contributes to the development of age-related pathologies affecting both the heart and the vasculature In particular evidence indicates that aging-associated alterations in inflammatory and pro-fibrotic pathways are critically involved in the etiology of age-related declines The study team hypothesize that mTOR antagonism with RAPA will improve detrimental age-related pathologies affecting the heart in elderly humans
Purpose of Sub-study E - Rapamycin and cMRI to evaluate cardiac function
The over-arching hypothesis is that RAPA treatment will effect simultaneous improvement in parameters known to be negatively impacted by aging For example systemic inflammation is higher in older individuals and contributes to the development of age-related pathologies affecting both the heart and the vasculature In particular evidence indicates that aging-associated alterations in inflammatory and pro-fibrotic pathways are critically involved in the etiology of age-related declines The study team hypothesize that mTOR antagonism with RAPA will improve detrimental age-related pathologies affecting the heart in elderly humans
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 5P30AG044271-07 | NIH | None | httpsreporternihgovquickSearch5P30AG044271-07 |